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Abstract
Background: The tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics are
poorly controlled in sub-Saharan Africa, where highly active antiretroviral treatment (HAART) has
become more freely available. Little is known about the clinical presentation and outcome of TB in
HIV-infected children on HAART.
Methods: We performed a comprehensive file review of all children who commenced HAART at
Tygerberg Children's Hospital from January 2003 through December 2005.
Results: Data from 290 children were analyzed; 137 TB episodes were recorded in 136 children;
116 episodes occurred before and 21 after HAART initiation; 10 episodes were probably related
to immune reconstitution inflammatory syndrome (IRIS). The number of TB cases per 100 patient
years were 53.3 during the 9 months prior to HAART initiation, and 6.4 during post HAART
follow-up [odds ratio (OR) 16.6; 95% confidence interval (CI) 12.5–22.4]. A positive outcome was
achieved in 97/137 (71%) episodes, 6 (4%) cases experienced no improvement, 16 (12%) died and
the outcome could not be established in 18 (13%). Mortality was less in children on HAART (1/21;
4.8%) compared to those not on HAART (15/116; 12.9%).
Conclusion: We recorded an extremely high incidence of TB among HIV-infected children,
especially prior to HAART initiation. Starting HAART at an earlier stage is likely to reduce
morbidity and mortality related to TB, particularly in TB-endemic areas. Management frequently
deviated from standard guidelines, but outcomes in general were good.
Background
The tuberculosis (TB) epidemic is poorly controlled in
sub-Saharan Africa; the region that reports the highest TB
incidence rates and highest prevalence of human immun-
odeficiency virus (HIV) infection [1,2]. Prevention of
mother to child transmission (PMTCT) programs are
poorly established in many countries and in many
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instances fail to use potent antiretroviral regimens, result-
ing in huge numbers of HIV-infected children.
Childhood TB contributes significantly to the global TB
case load (15–20% of cases), [3-5] especially in Africa
where TB has been identified as a major respiratory cause
of death in children [6]. The high disease burden results
from ongoing TB transmission (poor epidemic control)
and increased vulnerability as a result of HIV-induced
immune compromise. Compared to HIV-uninfected chil-
dren, HIV-infected children demonstrate greater morbid-
ity and mortality from TB [5,7-11], as well as increased
risk of rapid disease progression [12], unsatisfactory treat-
ment response [7,8,13-15], and TB recurrence [13]. In
resource-limited settings, mortality rates among HIV-
infected children diagnosed with TB range from 20–35%
[5,8,9,13-15], but the TB outcome in the era of highly
active antiretroviral therapy (HAART) is less well docu-
mented.
With recent international efforts, HAART has become
more widely available. The South African government
supported the roll-out of HAART since 2004; all children
with severe immune suppression and/or clinical stage 3 or
4 disease are eligible. HAART reduces the HIV viral load,
which allows CD4 T-cell repletion and assists with the res-
toration of immunological function. Although complete
functional immune reconstitution is rarely achieved, the
beneficial effect of HAART in HIV-infected adults [16-19]
and children [20-23] is well documented. In HIV-infected
adults, HAART reduces the incidence of TB and the risk of
TB recurrence [18,24,25], it also improves survival rates
among TB patients [25-27]. A recent retrospective study
from South Africa demonstrated a three-fold reduction in
the incidence of TB in children on HAART compared to
those not on HAART [28]. Restoration of specific antimy-
cobacterial immune responses has been documented in
children receiving HAART [29]; two recent case series
described immune reconstitution inflammatory syn-
drome (IRIS)-related phenomena in children [30,31], but
the prevalence and presentation of these phenomena
require better description.
TB is regarded as a World Health Organization (WHO)
HIV stage 3 (intra-thoracic) or 4 (extra-thoracic) condi-
tion. However, the best time for the introduction of
HAART following a TB diagnosis remains uncertain;
WHO recommends introducing HAART at different time
points, starting earlier in the more immunocompromised
children or where response to TB treatment is poor [32].
Early introduction of HAART carries a higher risk of IRIS-
related phenomena, which may be misinterpreted as poor
treatment response, drug-related adverse events or TB/HIV
disease progression [30,33,34]; there is limited data in
children to guide clinical decision making.
WHO recommends standard TB treatment, irrespective of
the child's HIV status [22]. However, some uncertainty
about the optimal treatment duration remains, due to
reports of increased TB recurrence in HIV-infected chil-
dren not on HAART who received standard TB treatment
[6,7,23]. More information is required regarding TB recur-
rence in HIV-infected children and the influence of
HAART. There are also concerns regarding common toxic-
ities, drug interactions and treatment adherence if TB ther-
apy and HAART are given concurrently. The aims of this
study were to describe the clinical presentation and out-
come of all children on HAART, in whom TB was diag-
nosed either during pre-HAART screening or during post-
HAART follow-up.
Methods
We conducted a retrospective descriptive study; data were
collected by review of clinical files and chest radiographs.
The files of all HIV-infected children (aged <13 years) who
were initiated on HAART from 1 January 2003 through 31
December 2005 at Tygerberg Children's Hospital (TCH)
were reviewed. We collected data on all TB episodes from
the time of pre-HAART screening, defined as the 9 months
prior to HAART initiation, until the end of the study
period. Each TB episode was studied from treatment initi-
ation until completion (where data was available), or
death. Children who received single or dual antiretroviral
therapy and children enrolled in TB prophylaxis trials
were excluded.
Data collection
Study subjects were identified from two sources; 1) the
TCH pharmacy database, which record all children who
received HAART since 2004, and 2) the HAART register
kept at the HIV clinic that identifies children who accessed
HAART prior to 2004. Clinical information was collected
through a systematic search of clinical files kept at the HIV
clinic and/or medical records. Demographic data, details
of HIV clinical staging and HAART, as well as TB presenta-
tion and diagnosis were recorded for each episode. A chest
radiograph (CXR) taken at the time of TB diagnosis was
reviewed by a single childhood TB expert blinded to all
clinical information. The outcome of each TB episode was
assessed and categorized according to pre-defined out-
comes.
Definitions
HIV infection was defined as two positive HIV ELISA tests
if over 18 months of age or a positive HIV RNA PCR test if
below 18 months of age. HIV staging was defined accord-
ing to the World Health Organization (WHO) clinical and
revised immunological classification for HIV-associated
immune-deficiency in infants and children (February
2006); TB was taken into account when allocating clinical
categories. TB diagnosed more than 9 months prior toBMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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HAART initiation was recorded as previous TB. A TB epi-
sode included all TB diagnoses made within 9 months of
HAART initiation or any time thereafter up to 31 Decem-
ber 2005. IRIS was defined as new mycobacterial disease
and/or worsening of pre-HAART symptoms/signs
recorded within the first 6 months after HAART initiation,
in a child that demonstrated good immunological recov-
ery and viral suppression.
The certainty of TB diagnosis was categorized as; 1) bacte-
riologically confirmed, where M. tuberculosis cultures were
positive; 2) radiologically indicative, where cultures were
negative or unavailable, but the CXR [or another radio-
graphic investigation such as a computed tomography
(CT)-scan] was considered indicative of TB; 3) clinically
suspected, where cultures were negative or unavailable
and radiographic evidence missing or not indicative of TB,
but the child presented with a persistent cough for more
than 2 weeks and/or fever for more than 1 week and/or
recent failure to thrive, together with documented TB con-
tact and/or a positive tuberculin skin test (TST, defined as
an induration size ≥5 mm using the Mantoux test). Alter-
natively specific organ involvement, such as neck stiffness,
a depressed level of consciousness, focal signs and cere-
brospinal fluid findings indicative of TB meningitis. Posi-
tive treatment response provided additional supportive
evidence. Not TB was the outcome if an alternative diag-
nosis was established (2 cases) and/or where critical
review of the data provided insufficient evidence to sup-
port a diagnosis of TB (this occurred in 1 case).
Standard TB treatment comprised of isoniazid (INH),
rifampicin (RMP) and pyrazinamide (PZA) for 2 months,
followed by INH and RMP for 4 months; expanded regi-
mens included ethambutol (EMB) and/or ethionamide
(ETH) in addition. Alternative TB regimens included sec-
ond line TB drugs such as ofloxacin, ciprofloxacin, ami-
kacin, and/or cycloserine/terizidone. The outcome of each
TB episode was categorized as; 1) cure, where there was
good clinical response to treatment and follow-up cul-
tures were negative in an episode of bacteriologically con-
firmed TB; 2) treatment completed and child well, where
the response to treatment was good in an episode that did
not have bacteriological confirmation, or where follow-
up cultures were not available; 3) improvement, where
some symptoms persisted but the child was assessed as
clinically better than at TB diagnosis; 4) no improvement,
where the original symptoms persisted or worsened; and
5) death, if child died before completing TB treatment.
Outcomes 1–3 were grouped together as positive out-
come. An adverse event was defined as any event resulting
in modification of TB treatment or HAART either because
of suspected drug toxicity or as a precautionary measure.
Statistical analysis
Data were entered into a Microsoft SQL Server database.
Statistical calculations were performed using SAS version
9.1. Descriptive analyses were performed and the Z test for
independent proportions was used to calculate the differ-
ence between two sample proportions. Differences in
median values were calculated by the Mann-Whitney-Wil-
coxon test. A p-value of <0.05 was considered significant.
The number of TB cases per 100 patient years was calcu-
lated using the formula; number of cases × 12/observation
period in months × 100/number of patients observed.
This calculation was performed in two groups of children;
1) those where TB was diagnosed in the 9 months prior to
HAART initiation and 2) those where TB was diagnosed
during the post-HAART follow up period (average 13.5
months).
Ethics approval was granted by Stellenbosch University's
Committee for Human Research (project number N06/
08/167).
Results
During the study period 296 children started HAART; 6
folders could not be located. Of the remaining 290 chil-
dren 140 (48.3%) received TB treatment; 4 cases had
incomplete data. The final group analyzed consisted of
136 children, of whom one had two TB episodes during
the study period. Figure 1 provides a schematic overview
of the study population. Table 1 reflects basic demo-
graphic data, HIV staging, weight and previous TB epi-
sodes recorded at HAART initiation in all 140 children
treated for TB. There were significantly more children with
severe immunosuppression among those diagnosed with
TB compared to those without TB (WHO severe CD4
depletion 117/140 versus 94/150, p < 0.0001), and more
children with TB were under their expected weight for age
(<60% EWA 29/140 versus 14/150; 60–80% EWA 64/140
versus 46/150, p < 0.01 for both).
Table 2 reflects 137 TB episodes for which sufficient data
could be obtained. A single child with two TB episodes,
the first episode before and the second 5 weeks after
HAART, is represented twice. In total, 116/137 (84.7%)
TB episodes occurred prior to HAART initiation. Of these
children 4 started TB treatment and HAART simultane-
ously, 80 were still on TB treatment when HAART was
commenced and 22 first completed their TB treatment;
the date of TB treatment completion was unknown in 10.
The number of TB cases per 100 patient years, calculated
for the different groups were; 1) 53.3/100 patient years
during the 9 months prior to HAART initiation, and 2)
6.4/100 patient years during the period of post-HAART
follow-up (average 13.5 months) [odds ratio (OR) 16.6;
95% confidence interval (CI) 12.5–22.4].BMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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Clinical presentation
The presence or absence of a TB index case was recorded
in 107/137 (78%) episodes; positive contact was identi-
fied in 53/107 (49.5%). In 29, the TB contact was an adult
member of the household who had started TB treatment
in the preceding 6 months. Sputum smear results were
recorded in 10 cases; 2 were positive. In 116/137 (84.7%)
episodes the child presented with at least one sign or
symptom suggestive of TB; 2 or more symptoms were
recorded in 70/137 (51.1%). The most common present-
ing symptoms were weight loss or failure to thrive (90;
65.7%), cough >2 weeks (50; 36.5%), and intermittent
fever >1 week (43; 31.4%). Lethargy or irritability were
recorded in 33 cases (3 had TB meningitis) and 14 had a
history of recurrent or persistent chest infections.
Table 3 demonstrates the spectrum of mycobacterial dis-
ease recorded in the 136 children analyzed. Five children
treated for TB had concurrent Mycobacterium bovis bacillus
Calmette-Guérin (BCG) axillary adenitis. Two cases of
NTM disease were initially treated for TB; 1 cultured M.
fortuitum from 2 gastric aspirates, the other had a single
positive gastric aspirate culture of an unspecified NTM.
Among the 33 M. tuberculosis cases with extra-thoracic dis-
ease manifestations, the sites most commonly involved
were abdomen (10; 30.3%), central nervous system (9;
27.3%), miliary disease (9; 27.3%), cervical/axillary
lymph nodes (4; 12.1%), and pericardium (2; 6.1%).
There were also 2 cases of probable congenital TB with
hepatomegaly.
Table 4 reflects the presenting features; CXR data and/or
culture results were available in 107 (89.1%) cases, the
remainder was classified as "clinically suspected TB". Bac-
teriologically confirmed TB was diagnosed pre-HAART in
40/116 (35%) and post-HAART in 6/21(29%) cases; the
number of bacteriologically confirmed TB cases per 100
patient years were 18.3 pre-HAART and 1.8 post-HAART.
Three cases were classified as "not TB". Of these, one child
presented with weight loss, marasmus and liver dysfunc-
tion, but was ultimately diagnosed with candida septicae-
mia. There was no history of TB contact, 2 gastric aspirates
yielded negative cultures and the CXR was normal. In the
other 2 cases a NTM organism was cultured. There was no
statistical difference in TST reactivity, contact history or
proportion with suggestive symptoms among the diag-
nostic categories. TST results were positive in only 16/73
(22%) children with bacteriologically confirmed and/or
radiologically indicated TB.
Among children who started HAART before the end of TB
therapy, few developed clinical exacerbation of disease
after HAART initiation, apart from 2 who developed con-
current BCG axillary adenitis. Of the 14 children diag-
nosed with TB within 6 months of HAART initiation, 12
had severe and 2 advanced immune suppression. Ten chil-
dren had excellent immunological and virological
responses following HAART [mean CD4% before and
after HAART (11.2% versus 28.2%); mean HIV viral load
before and after HAART (log 6.1 versus log1.1)], while 3
showed poor response and one was lost to follow-up.
Among the 10 children with vigorous immune reconstitu-
tion, those most likely to be true cases of IRIS, all episodes
occurred between 2 weeks and 4 months after HAART ini-
tiation; 5 were bacteriologically confirmed cases. CXR's
were not remarkable for extensive or cavitating disease.
TB treatment
Of the 137 TB episodes analyzed, 91 (66%) were initially
treated with the standard 3-drug regimen and 46 (34%)
were treated with expanded or alternative regimens.
Schematic overview of the study population Figure 1
Schematic overview of the study population.BMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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Expanded regimens were given for cavitating or extensive
intrathoracic disease (3), extra-thoracic or miliary disease
(19), previous TB (10) and for concurrent M. bovis BCG
disease (2). Alternative regimens were given for drug-
resistant disease (3), pre-existing hepatitis (3), extensive
intra-thoracic disease (1), and for concurrent M. bovis
BCG disease (2); reason unclear (3). In 29 (21%) cases the
initial TB regimen was subsequently changed; reasons for
changing to a different regimen are reflected in Table 5.
Adverse events were noted in 13/137 (9.5%) episodes: 8
had raised liver enzymes (>5 times the upper limit of nor-
mal), 4 had skin reactions and 1 developed anaemia and
thrombocytopenia. Table 6 outlines the adverse events
recorded, their likely causation and temporal relationship
to TB treatment and HAART. Only 7/137 (5%) events
were probably drug related: 5 cases of raised liver enzymes
and 2 urticarial reactions. Drug related adverse events
occurred in 3 children on concurrent HAART and TB treat-
ment. TB treatment was suspended or modified in all
cases with raised liver enzymes, except in one case where
an elevated alanine transaminase level done routinely for
HAART toxicity monitoring went unnoticed until the
child's next visit a month later, by which time it had
resolved.
The outcome related to the duration of treatment is
reflected in Table 7; the 3 children deemed not to have
had TB were not included in this analysis. Of 134 TB epi-
sodes, 33 (25%) were treated for 6 months; 15 were
treated for <6 months of whom 12 died and 3 (none with
bacteriologically confirmed or radiologically certain TB)
had a positive outcome. Thirty eight (28%) episodes were
treated for 7–9 months; 9 had TB previously, 2 had con-
current BCG adenitis, 3 experienced initial deterioration
and the remaining 24 were treated for longer due to their
HIV status. Nineteen (14%) episodes were treated for 10–
12 months; 4 had drug-resistant disease, 2 INH-monore-
sistant and 2 multidrug-resistant (MDR) TB; 1 received
alternative treatment due to a drug-related adverse event;
4 had extensive intrathoracic disease and/or experienced
disease progression on treatment; 1 developed concurrent
BCG adenitis. It was uncertain why the remaining 9 chil-
dren received prolonged treatment. Seventeen (13%) epi-
Table 1: Basic demographic data, HIV staging, weight categorization and previous TB episodes recorded at the time of HAART 
initiation, comparing those treated for TB to those not treated for TB
All children who 
received HAART
Treated for TB during 
study period
Not treated for TB 
during study period
p-value
Total number 290 (100%) 140#‡ (100%) 150## (100%)
Gender
Male 143 (49%) 67 (48%) 76 (51%) 0.43
Age (months)
Range/median 1–160/23.5 2–140/19 1–160/33.5 0.08
WHO HIV staging*
CD4 depletion
not significant 22 (8%) 4 (3%) 18 (12%) NA
mild 26 (9%) 9 (6%) 17 (11%) 0.14
advanced 31 (11%) 10 (7%) 21 (14%) 0.06
severe 211 (73%) 117 (84%) 94 (63%) <0.001
Clinical stage
II 15 (5%) 1 (1%) 14 (9%) NA
III 128 (44%) 50 (36%) 78 (52%) <0.01
IV 144 (50%) 89 (63%) 55 (37%) <0.001
Unknown 3 (1%) 0 (0%) 3 (2%) NA
Weight categories
<60% EWA** 43 (15%) 29 (21%) 14 (9%) <0.01
60–80% EWA 110 (38%) 64 (46%) 46 (31%) <0.01
80–100% EWA 92 (32%) 34 (24%) 58 (39%) <0.01
>100% EWA 25 (9%) 6 (4%) 19 (13%) 0.01
Unknown 20 (7%) 7 (5%) 13 (8%) 0.22
Previous TB
1 episode 76 (26%) 19 (14%) 57 (38%) <0.001
≥2 episodes 12 (4%) 7 (5%) 5 (3%) NA
*WHO, World Health Organization immunological classification of HIV-associated immunodeficiency in infants and children, 2006
**EWA, expected weight for age
# Includes 4 children subsequently excluded due to incomplete data
## Includes 5 children with BCG disease only, who were excluded from further TB analysis
NA – not applicable, sample proportions too small for Z testBMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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sodes received TB treatment for >12 months; 7 had
confirmed MDR TB, 1 had pre-existing hepatitis that
necessitated alternative therapy, 4 had persistent culture
positive or progressive disease after 3 months of treat-
ment, 4 experienced drug related adverse reactions, 1
developed concurrent BCG adenitis and another reported
2 previous episodes of TB.
TB outcome
A positive outcome was achieved in 97/137 (71%) epi-
sodes: cure in 17 (12%), treatment completed and child
well in 45 (33%), improved in 35 (26%). In 6 (4%) cases
no improvement was documented; 16 (12%) children
died before TB treatment was completed. Outcome could
not be established in 18 (13%) episodes, where children
were lost to follow up. All 6 episodes that failed to show
improvement were diagnosed before HAART initiation; 1
had disseminated drug-susceptible TB meningitis, 1 had
biopsy-proven lymphoid interstitial pneumonitis with
extensive bronchiectasis, the remaining 4 were all severely
immunocompromised and had significant co-morbidi-
ties. Positive outcomes were achieved in 80/116 (69%) TB
episodes diagnosed pre-HAART, 11/14 (78%) episodes
diagnosed <6 months and 6/7 (86%) episodes diagnosed
≥6 months post-HAART. HAART was introduced <2
months after the start of TB therapy in 30 children, all had
advanced/severe HIV disease; the outcome was not docu-
mented in 4 cases. A good outcome was achieved in 17/26
Table 2: All children diagnosed with TB during the study period, differentiating between those diagnosed before and after HAART 
initiation
Children treated for TB TB diagnosed <9 
months prior to 
HAART
TB diagnosed <6 
months after HAART
TB diagnosed ≥6 
months after HAART
Total number# 137 (100%) 116 (100%) 14 (100%) 7 (100%)
Gender: Male 64 (47%) 54 (47%) 6 (43%) 4 (57%)
Age (months):
Range/median 2–140/18 2–135/20 3–140/17 3–75/17
HIV staging
WHO* CD4 depletion
not significant 5 (4%) 3 (3%) 1 (7%) 0 (0%)
mild 9 (7%) 7 (6%) 0 (0%) 2 (29%)
advanced 10 (7%) 7 (6%) 2 (14%) 1 (14%)
severe 113 (82%) 98 (84%) 11 (79%) 4 (57%)
WHO clinical stage
II 1 (1%) 0 (0%) 1 (7%) 0 (0%)
III 47 (34%) 40 (34%) 5 (36%) 2 (29%)
IV 89 (65%) 76 (66%) 8 (57%) 5 (71%)
Weight categories
<60% EWA** 27 (20%) 24 (21%) 3 (21%) 0 (0%)
60–80% EWA 64 (47%) 51 (44%) 7 (50%) 6 (86%)
80–100% EWA 34 (25%) 31 (27%) 3 (21%) 0 (0%)
>100% EWA 6 (4%) 5 (4%) 1 (7%) 0 (0%)
Unknown 6 (4%) 5 (4%) 0 (0%) 1 (14%)
Previous TB
1 episode 18 (13%) 12 (10%) 5 (36%) 1 (14%)
≥2 episodes 7 (5%) 4 (3%) 1 (7%) 2 (29%)
#4 folders with incomplete data excluded. 1 child with 2 TB episodes is represented twice.
*WHO, World Health Organization immunological classification of HIV-associated immunodeficiency in infants and children, 2006
**EWA, expected weight for age
Table 3: Spectrum of mycobacterial disease recorded in HIV-
infected children treated for TB
Diagnosis Number (%)
M. tuberculosis 135 (98.5)
Intra-thoracic 102 (74.5)
Extra-thoracic 5 (4)
Intra- and extra-thoracic* 28 (20)
Concurrent M. bovis BCG** 5
Localized (axillary adenitis) 5
Distant or disseminated 0
Non-tuberculous mycobacteria
Pulmonary# 2 (1.5)
TOTAL 137 (100%)
*9 cases of miliary TB are included in this group
**BCG: bacillus Calmette-Guérin
#Non-tuberculous mycobacteria cultured from gastric aspiratesBMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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(65%) and 9/26 (35%) had a poor outcome; 8 died and 1
did not improve.
Table 8 reflects demographic data, TB diagnosis and HIV
staging at death of the 16 children who died before com-
pleting TB therapy. It also reflects the timing of death in
relation to the initiation of TB treatment and HAART.
Apart from 1 child who developed TB <3 months after
starting HAART, 15/16 (93.8%) deaths occurred in chil-
dren diagnosed with TB before HAART initiation. The
child on HAART died in the third month of TB treatment
from intestinal perforation secondary to colitis. The etiol-
ogy was not confirmed, but might have been related to
IRIS as the child showed good immunological recovery;
CD4 count at HAART initiation 19% versus 27% at death.
Mortality was reduced in those already on HAART (1/21;
4.8%) compared to children who started HAART after TB
diagnosis [15/116; 12.9% – odds ratio (OR) 0.34 95%
confidence interval (CI) 0.01–2.46].
Of the 15 children first diagnosed with TB that died, 8
(53%) started HAART within 2 months of commencing
TB treatment. Six of the 8 deaths occurred early (within 3
weeks of HAART initiation); 5 were severely immunocom-
promised (2 died of pneumonia, 3 had chronic gastroen-
teritis with/without severe electrolyte disturbances and/or
septicaemia) and the sixth child died as a result of co-
existent congenital heart disease. All 6 were infants (<1
year of age). Two children died later in the course of TB
treatment, 1 died 5 months into TB treatment and 3
months after HAART initiation from disseminated MDR
TB, 1 died 3 months into TB treatment and 2 months after
HAART from bacterial pneumonia.
The remaining 7 deaths occurred in children who com-
menced HAART ≥2 months after starting TB therapy. Four
children died <6 months after HAART initiation; 1 child
with chronic lung disease and culture-confirmed TB died
9 days later from bacterial pneumonia, 1 died 3 weeks
later from intestinal perforation secondary to Entamoeba
enterocolitis infection and septicaemia, 1 infant with mil-
iary TB died 2 months later from "aspiration pneumonia",
1 child with pulmonary NTM disease died 1 month after
HAART initiation from progressive pneumonia. Three
children with culture-confirmed TB died ≥ 6 months after
HAART initiation; 1 from bacterial pneumonia and septi-
caemia, 1 developed severe upper airway obstruction of
uncertain etiology and 1 died from MDR TB meningitis.
Four deaths may have been partly attributable to IRIS; two
cases, 1 with intestinal perforation and 1 with acute upper
airway obstruction, showed good immune recovery at
death compared to baseline, but occurred more than 5
months after HAART initiation. Two other deaths also
demonstrated excellent immune recovery on HAART; one
child with MDR TB developed multiple TB abscesses 3
Table 4: Presenting features of TB episodes, differentiated according to level of diagnostic certainty
TB diagnostic category Total number (%) TB contact Positive TST* Suggestive symptoms**
Bacteriologically 
confirmed
46 (100) 16 (33) 12 (25) 37 (80)
Radiologically indicated 27 (100) 9 (33) 4 (15) 25 (93)
Clinically suspected 61 (100) 28 (46) 17 (29) 51 (82)
Not TB 3 (100) 0 (0) 0 (0) 3 (100)
TOTAL 137 (100) 53 (39) 33 (24) 116 (85)
*TST, tuberculin skin test
**Persistent cough for >2 weeks and/or fever for >1 week and/or recent failure to thrive and/or specific organ involvement suggestive of TB
Table 5: Reasons for changing the TB treatment regimen in episodes treated initially with standard or expanded regimens
Reason for regimen change Initial regimen Total (%)
HRZ* HRZ ± Eth ± E*
Persistent culture-positive/
progressive disease
10 2 12 (38)
Drug resistance 3 4 7 (22)
Adverse event# 36 9  ( 2 8 )
M. bovis BCG/NTM** 3 1 4 (12)
Total (%)## 19 (59) 13 (41) 32 (100)
*H = isoniazid, R = rifampicin, Z = pyrazinamide, Eth = ethionamide, E = ethambutol,
**M. bovis BCG = Mycobacterium bovis Bacillus Calmette-Guérin disease, NTM = non-tuberculous mycobacteria disease
#In total there were 13 adverse events, only 9 appear in this table as the others did not necessitate a regimen change (2 started on alternative TB 
regimens, 1 stayed on the initial regimen, 1 had all treatment suspended)
##In total 32 regimen changes were recorded in 29 cases; 3 changed regimens twiceBMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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Table 6: Adverse events recorded during TB treatment according to the type of event, likely cause and relation to TB treatment and/
or HAART
Type of 
adverse event
Likely cause Relation to 
TB Rx
Relation to 
HAART
TB Rx 
regimen
TB Rx change HAART 
outcome
Clinical 
outcome
Raised liver enzymes n = 8
Transaminitis 
(severe*)
Auto-immune 
haemolysis
6 weeks No HAART HRZE Alternative Rx 3 
months
N/A Resolved
All enzymes 
(severe*)
Uncertain 5 months 1 month before 
TB Rx
HRZEO Stopped Suspended 2 
months
Resolved
Raised ALT 
(severe*)
TB drugs 2 months >2 months after 
TB Rx
HRZE Unchanged Unchanged Resolved
All enzymes 
(moderate*)
TB drugs (PZA) 1 week No HAART HRZE Alternative Rx 6 
months
N/A Resolved
Transaminitis 
(severe*)
TB drugs (PZA) 1 week 1 month before 
TB Rx
HRZE Alternative Rx 3 
months
Suspended 1 
week
Resolved
Raised 
canalicular 
enzymes 
(severe*)
Uncertain 4 months >2 months after 
TB Rx
HRZ Alternative Rx 2 
months
Unchanged Resolved
All enzymes 
(mild*)
CMV disease 2 months None HRZEth Alternative Rx 1 
month
N/A Died
Transaminitis 
(severe*)
Klebsiella sepsis 3 weeks 1 month after 
TB Rx
HRZE Alternative Rx 1 
day
Suspended Died
Skin reaction n = 4
Urticarial PZA 1 day None HRZE PZA stopped N/A Resolved
Mild 
unspecified
Uncertain 9 months >2 months after 
TB
HZEEthAT Unchanged Unchanged Resolved
Urticarial Possibly PZA 1 day None HRZ Alternative Rx 2 
months
N/A Resolved
Urticarial Uncertain 2 months <2 months after 
TB
HRZ Alternative Rx 1 
month
Suspended 1 
month
Resolved
Bone marrow suppression n = 1
Anaemia and 
low platelets
Sepsis 3 weeks None HRZEth Suspended N/A Died
PZA/Z = pyrazinamide, H = isoniazid, R = rifampicin, E = ethambutol, Eth = ethionamide, O = ofloxacin, A = amikacin, T = terizidone, Strep = 
streptomycin, Cipro = ciprofloxacin, CMV = cytomegalovirus; N/A = not applicable
*Degree of enzyme elevation: mild = 2–5x normal value; moderate = 5–10x normal value; severe = >10x normal value
Table 7: Outcome of TB episodes in relation to duration of TB treatment
TB outcome Duration of TB treatment Total (%)
<6 months 6 months 7–9 months 10–12 months >12 months Unknown
Cure 144170 1 7  ( 1 2 )
Clinically well 11 7 1 57 3 0 4 3  ( 3 2 )
Improved 11 0 1 37 3 0 3 4  ( 2 7 )
Not improved 003201 6  ( 4 )
Death before 
end of TB 
treatment
1 2 02110 1 6  ( 1 2 )
LTF/TFO/
Unknown
02113 1 1 1 8  ( 1 3 )
Total (%) 15 (11) 33 (25) 38 (28) 19 (14) 17 (13) 12 (9) 134(100)
LTF = lost to follow-up; TFO = transferred outBMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
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weeks after HAART and died shortly thereafter, another
child with MDR TB had TB meningitis died from acute
hydrocephalus 5 months after HAART. However, it is
impossible to establish with certainty whether IRIS was a
contributory cause of death in these children.
Discussion
During the study period, 48% of HIV-infected children
received TB treatment. This confirms the high TB burden
experienced by HIV-infected children in TB endemic
areas. Children with TB were significantly more immuno-
compromised and malnourished than those without TB,
which may relate to the severity of the underlying HIV dis-
ease and/or reflect the detrimental effects of the TB itself.
Most children were only commenced on HAART once
they had advanced HIV disease (83% had WHO advanced
or severe immune suppression), reflecting the large
number of children who had been awaiting access to
HAART, as well as conservative eligibility criteria. The
high proportion of children with previous TB, among
those not diagnosed with TB during the study period, can
be explained by their relatively high mean age (34
months) compared to those who were diagnosed with TB
(mean age 19 months). In this TB-endemic setting it is
expected that older children would be significantly more
likely to have had a previous episode of TB.
Most TB episodes were diagnosed in the 9 months prior to
HAART initiation, during which time a diagnosis of TB is
actively excluded. The number of TB diagnoses made pre-
HAART was five times greater than post-HAART, which is
even greater than the three fold reduction reported by
Martinson et al.[28]. When calculating the number of TB
cases per 100 patient years there was an eight fold reduc-
tion in TB episodes (53.3 versus 6.4), comparing the 9
months pre-HAART period to the post-HAART period.
This was not a manifestation of overzealous diagnosis in
the pre-HAART period, as the striking observation was
even more pronounced when only bacteriologically con-
firmed cases were taken into account (18.3 versus 1.8).
The reduction achieved is similar to that recorded with the
use of universal INH preventive therapy [35]. It must be
pointed out that the number of TB cases among those not
on HAART may have been inflated by the fact that TB was
frequently the presenting disease that lead to the diagno-
sis of HIV-infection and HAART initiation, especially
before the institution of effective PMTCT programs and
routine testing of HIV-exposed babies.
The clinical presentation of TB in our cohort was similar
to what has previously been described [5,7-10] The pres-
ence or absence of a TB index case was recorded in less
than 80% of children. This is an important oversight as
careful scrutiny of the index case often provides important
clues to identify drug-resistant disease in child contacts.
Another interesting observation, although numbers were
very small, is that the majority of index cases with docu-
mented sputum smear results were sputum smear-nega-
tive. Adults with sputum smear-negative pulmonary TB
do transmit disease, albeit at a reduced rate. Current WHO
guidelines do not recognize the potential transmission
risk posed by exposure to a sputum smear-negative index
case, especially if this is the child's mother or primary car-
egiver [36]. Weight loss or failure to thrive was the most
frequent presenting symptom, but this may be caused by
advanced HIV disease itself or by other HIV-related oppor-
tunistic infections. In addition accurate symptom defini-
tion, which is essential for optimal specificity [37], is
impossible with retrospective analysis of routine clinical
data.
The disease spectrum observed is comparable to that
reported in HIV-uninfected children from the same area,
although the number of children with disseminated (mil-
Table 8: Summary of all children who died before completing TB 
therapy; demographic data, HIV staging, TB diagnosis and 
timing of death in relation to TB treatment and HAART 
initiation
Number 
(%)
Total deaths 16 (100)
Gender (Male) 8 (50)
Age (months); Median (range) 11.5 (4–110)
WHO* CD4 depletion
not significant 2 (13)
mild 0 (0)
advanced 1 (6)
severe 13 (81)
WHO clinical stage
III 1 (6)
IV 15 (94)
Disease manifestation
Intra-thoracic TB 8 (50)
Extra- and intra-thoracic TB 5 (31)
Culture-confirmed M. tuberculosis 7 (44)
MDR** TB 2 (13)
TB & BCG# disease 1 (6)
NTM## 1 (6)
Timing of death in relation to start of TB 
treatment
<2 months 6 (38)
≥2 months 10 (62)
Timing of death in relation to HAART 
initiation
<2 weeks 5 (31)
2 weeks – 6 months 9 (56)
>6 months 2 (13)
*WHO, World Health Organization immunological classification for 
HIV-associated immunodeficiency in infants and children, 2006
**MDR – multi-drug resistant (resistant to at least INH and RMP)
#BCG – M. bovis Bacillus Calmette Guérin;
##NTM – non-tuberculous mycobacteriaBMC Pediatrics 2008, 8:1 http://www.biomedcentral.com/1471-2431/8/1
Page 10 of 12
(page number not for citation purposes)
iary) disease was significantly increased [9/134 (6.7%) vs
11/414(2.7%); OR 2.6, 95% CI 1.0–7.0] [38]. The timing
of HAART introduction was largely dependent on the
child's clinical condition; being introduced earlier in chil-
dren with severe immune suppression. IRIS was not
prominent in this group; in fact, disease progression in the
absence of HAART often prompted its early initiation. The
incidence of TB IRIS (7,4%) is slightly higher that that
reported by Puthanakit et al.[30] and was higher among
those with bacteriologically confirmed TB (4/46; 8.7%),
compared to those without bacteriologically confirmed
TB (6/88; 6.8%).
This study documents the frequency with which the man-
agement of TB in HIV-infected children deviates from
standard protocol. Despite local [39] and international
guidelines [40], therapy often has to be individualized. In
this cohort, only 75/137 (55%) of TB episodes were
treated with the standard 3-drug TB regimen; 33/137
(24%) for the standard 6 months. The proportion of chil-
dren who received expanded treatment regimens was
greater than that expected from the number of extra-tho-
racic and/or drug-resistant cases, which reflects extensive
disease, high levels of co-morbidity and caution among
clinicians who treat HIV-infected children with TB.
Adverse events that were probably drug-related occurred
in only 7 children of whom 3 were on concurrent HAART.
Although the absolute numbers are small it indicates that
more than 5% of children may have experienced drug-
related adverse events, with a further 4% experiencing
non-drug-related adverse events. In total, adverse events
necessitated treatment modification in nearly 10% of
cases. This is important, as second line TB drugs are not as
effective as first-line regimens, are more often associated
with drug-related adverse events and result in longer treat-
ment durations, with a concomitant increased risk of drug
interactions and poor adherence. Although HAART was
only suspended in a single child, stopping HAART for any
period of time may impact negatively on the long-term
prognosis of HIV-infected children.
The cohort in general did well, with 71% reporting posi-
tive outcomes. TB diagnosed after HAART initiation was
associated with excellent outcomes. Although the reduced
mortality recorded in children on HAART, compared to
those not on HAART, at the time of TB diagnosis failed to
reach statistical significance, no child who had been on
HAART for more than 6 months prior to the TB episode
died. Among the children who died, the majority had
advanced HIV disease, and most died of HIV-related con-
ditions other than TB. It is therefore not surprising that the
group where HAART was introduced within 2 months of
TB treatment had the worst outcomes, as the timing of
HAART introduction was determined by the severity of
the underlying HIV disease (clinical and immunological
stage of the patient). These were young, severely immune
suppressed and critically ill children in whom HAART was
often given as a last resort. In this respect it is important to
note that despite their grave clinical condition, 65% of
these children survived with positive outcomes.
The early introduction of HAART was rarely (<10% of
cases) associated with drug related adverse events or sig-
nificant immune reconstitution phenomena. Two cases of
BCG adenitis developed shortly after HAART initiation
and probably represent BCG IRIS disease [41]. Although
IRIS may have contributed to 4 deaths this remains highly
speculative, as 2 deaths occurred relatively late (more than
5 months after HAART initiation) and the other 2 had
progressive MDR TB; the progressive and drug-resistant
nature of their disease was probably responsible for their
demise.
Being retrospective, our study is limited by incomplete
data and missing records. However, we were able to
retrieve essential data in the vast majority of children
(>95%) and believe that the information provided allows
accurate assessment of the diagnostic challenges related to
TB and HIV in everyday clinical practice. Although this is
a hospital-recruited cohort, significant selection bias is
unlikely as, during the study period, TCH functioned as
the only point of access to HAART for children from the
surrounding areas.
Conclusion
The study confirms the high incidence of TB among HIV-
infected children in TB endemic settings. Although the
management of TB in HIV-infected children may be com-
plicated, the majority of children achieved a positive out-
come. HAART initiation was followed by a substantial
reduction in the incidence of TB, yet children only
accessed HAART at an advanced stage of HIV disease. For
HIV-infected children living in TB endemic areas, starting
HAART at an earlier stage is likely to reduce TB-related
morbidity and mortality.
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